ISSN: 1476-0584
Journal Home
Journal Guideline
Expert Review of Vaccines Q1 Unclaimed
Expert Review of Vaccines is a journal indexed in SJR in Drug Discovery and Pharmacology with an H index of 105. It has a price of 4000 €. It has an SJR impact factor of 1,412 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,412.
Expert Review of Vaccines focuses its scope in these topics and keywords: vaccines, vaccine, diseases, neglected, pcv, hiv, iii, immunoinformatics, impact, designplantbased, ...
Type: Journal
Type of Copyright:
Languages: English
Open Access Policy:
Type of publications:
Publication frecuency: -
4000 €
Inmediate OANPD
Embargoed OA0 €
Non OAMetrics
1,412
SJR Impact factor105
H Index110
Total Docs (Last Year)409
Total Docs (3 years)7915
Total Refs2013
Total Cites (3 years)364
Citable Docs (3 years)5.1
Cites/Doc (2 years)71.95
Ref/DocOther journals with similar parameters
Protein & Cell Q1
Molecular Therapy Q1
Nature Reviews Drug Discovery Q1
Medicinal Research Reviews Q1
Cell Chemical Biology Q1
Compare this journals
Aims and Scope
Best articles by citations
Serologic correlates of protection for evaluating the response to meningococcal vaccines
View moreUse of attenuated paramyxoviruses for cancer therapy
View moreCurrent status and future prospects for a vaccine against schistosomiasis
View moreAn adolescent and adult formulation combined tetanus, diphtheria and five-component pertussis vaccine
View moreTime for T? Immunoinformatics addresses vaccine design for neglected tropical and emerging infectious diseases
View moreConsultation on interactions between National Regulatory Authorities and National Immunization Technical Advisory Groups
View morePlant production systems for vaccines
View moreVirus-like antigen display for cancer vaccine development, what is the potential?
View moreOverview of mimotopes and related strategies in tumor vaccine development
View moreIn-depth phylogenetic analysis of the hemagglutinin gene of influenza A(H3N2) viruses circulating during the 2016-2017 season revealed egg-adaptive mutations of vaccine strains
View morePneumococcal conjugate vaccines: emerging clinical information and its implications
View moreDevelopment of vaccines to prevent malaria in pregnant women: WHO MALVAC meeting report
View moreNonclinical safety evaluation of Escherichia coli heat-labile toxin mucosal adjuvant as a component of a nasal influenza vaccine
View morePertussis: should we improve intensive care management or vaccination strategies?
View moreThe immunization imperative
View moreProgress in filovirus vaccine development: evaluating the potential for clinical use
View moreInfluenza vaccination of pregnant women protects them over two consecutive influenza seasons in a randomized controlled trial
View moreMucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA
View moreNorwalk virus-like particles as vaccines
View moreReimmunization after hematopoietic stem cell transplantation
View moreCurrent status of GV1001 and other telomerase vaccination strategies in the treatment of cancer
View moreWhat do the next 100 years hold for pneumococcal vaccination?
View moreA systematic review about Streptococcus Pneumoniae serotype distribution in children in mainland of China before the PCV13 was licensed
View moreDesign of tuberculosis vaccine trials under financial constraints
View more
Comments